Teijin/Takeda Hyperuricemia Drug Febuxostat's U.S. Sales To Reach ¥10 billion
This article was originally published in PharmAsia News
Executive Summary
Teijin estimates that first year sales for hyperuricemia drug febuxostat will reach ¥10 billion ($110 million) and will peak at ¥50 billion